Kevin C. Reyes

San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
 
 

Kevin Reyes represents both private and public companies in a wide variety of corporate matters, including public securities offerings, mergers and acquisitions, venture financings, corporate governance, and securities law compliance matters. Mr. Reyes also advises investment banks in public financing transactions.

While attending the University of Southern California Gould School of Law, Mr. Reyes published a student note for the Southern California Interdisciplinary Law Journal, and served as a teaching fellow for the Legal Writing and Advocacy Program. During law school, he also served as a judicial extern for Judge Virginia A. Phillips in the US District Court for the Central District of California.

Mr. Reyes has advised on a broad range of corporate transactions, including numerous public and private company mergers, acquisitions, asset sales, and investments.

Significant matters include representing:

  • Callaway Golf Company in its US$2 billion stock-for-stock merger with Topgolf International, US$75 million acquisition of Ogio International, US$125 million acquisition of TravisMathew, and €418 million acquisition of German-based Jack Wolfskin
  • Viasat in its US$222 million stock-for-stock merger with RigNet and US$62 million acquisition of NetNearU
  • BioMed Realty Trust in its US$8 billion acquisition by affiliates of The Blackstone Group
  • Impact Biomedicines in its acquisition by Celgene Corporation for up to US$7 billion
  • Alphatec Spine in its acquisition of French-based EOS imaging via public tender offer and the US$80 million sale of its international business to Globus Medical
  • Excel Trust in its US$2 billion acquisition by affiliates of The Blackstone Group
  • Extra Space Storage in its US$1.4 billion acquisition of SmartStop Self Storage
  • Ligand Pharmaceuticals in its US$178 million acquisition of Open Monoclonal Technology
  • Agility Clinical in its sale to Precision Medical Group for proceeds of up to US$46 million
  • Aratana Therapeutics’ €33.3 million stock acquisition of Okapi Sciences and US$30 million cash and stock merger with Vet Therapeutics
  • Neurelis in its acquisition of Aegis Therapeutics
  • Pulse Electronics in a US$26 million going private transaction with Oaktree Capital Management
  • Zavante Therapeutics, in its stock-for-stock sale to Nabriva Therapeutics plc for up to US$125 million

Mr. Reyes has also advised numerous companies and underwriters on various public and private financings, including initial public offerings, PIPE financings, venture financings, private equity and debt offerings, and follow-on, and secondary public offerings, including representing:

  • Bridge Investment Group in its US$300 million initial public offering
  • Callaway Golf Company in connection with its follow-on offerings of equity and debt raising more than US$250 million
  • Crinetics Pharmaceuticals in its US$117 million initial public offering and several equity follow-on offerings
  • Essex Property Trust in senior notes offerings and at-the-market equity offerings raising more than US$2 billion
  • Extra Space Storage in equity and debt offerings raising more than US$875 million
  • Gossamer Bio in its US$317 million initial public offering and equity and debt follow-on offerings
  • Neurelis in its preferred stock financings with LYZZ Capital, HBM Healthcare Investments, and China Medical Systems, raising over US$150 million
  • ViaSat in equity and debt offerings raising more than US$1 billion
  • Airgain in its US$12 million initial public offering
  • Alphatec Spine in a US$18 million PIPE financing
  • Zavante Therapeutics in its Series A financing with Frazier Healthcare Partners, Longitude Capital, and Aisling Capital
  • A number of investment banks, including Barclays, BofA Merrill Lynch, BMO, Jefferies, J.P. Morgan, Piper Jaffray, and Stifel, in public offerings of equity securities for life sciences companies, including Applied Genetic Technologies Corporation, Glycomimetics, ACADIA Pharmaceuticals, Biocryst Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, Neurocrine Biosciences, and Sarepta Therapeutics
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.